PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
16794561-0	2007	Blockade of 5-HT2a receptors reduces haloperidol-induced attenuation of reward.	Haloperidol	37-48	5-hydroxytryptamine receptor 2A	Rattus norvegicus	12-18	
16220333-0	2005	ACP-103, a 5-HT2A/2C inverse agonist, potentiates haloperidol-induced dopamine release in rat medial prefrontal cortex and nucleus accumbens.	Haloperidol	50-61	5-hydroxytryptamine receptor 2A	Rattus norvegicus	11-17	
12225700-0	2002	SR46349-B, a 5-HT(2A/2C) receptor antagonist, potentiates haloperidol-induced dopamine release in rat medial prefrontal cortex and nucleus accumbens.	Haloperidol	58-69	5-hydroxytryptamine receptor 2A	Rattus norvegicus	13-20	
7516078-0	1994	In vivo dopamine-D2 and serotonin-5-HT2 receptor binding study of risperidone and haloperidol.	Haloperidol	82-93	5-hydroxytryptamine receptor 2A	Rattus norvegicus	24-48	
10462131-2	1999	In the present study, in vivo receptor occupancy of 5-HT2A, alpha1, dopamine D2 and D3 receptors by NRA0045 was assessed, based on in vivo and ex vivo receptor binding, and findings were compared to reference antipsychotic drugs (haloperidol, risperidone, clozapine).	Haloperidol	230-241	5-hydroxytryptamine receptor 2A	Rattus norvegicus	52-58	
9846274-5	1998	Drug occupation of 5-HT2A and dopamine D2 receptors in vivo examined with use of N-ethoxycarbonyl-2-ethoxy-1,2-dihydroquinoline (EEDQ) was 69.8% and 45.1%, respectively, after the acute administration of haloperidol (0.1 mg/kg) plus ritanserin (1 mg/kg).	Haloperidol	204-215	5-hydroxytryptamine receptor 2A	Rattus norvegicus	19-25	
9379848-3	1997	Regionally, 32 days treatment with haloperidol (3 mg/kg/day), sulpiride (100 mg/kg/day) or clozapine (10 mg/kg/day) resulted in a drop of approximately 30-40% in 5HT2C mRNA levels in both cortex and cerebellum, and decreases (or non-significant trends) of 15-40% in 5HT2A mRNA levels in hippocampus, brainstem and mid brain.	Haloperidol	35-46	5-hydroxytryptamine receptor 2A	Rattus norvegicus	266-271	
9181636-0	1997	8-OH-DPAT, a 5-HT1A agonist and ritanserin, a 5-HT2A/C antagonist, reverse haloperidol-induced catalepsy in rats independently of striatal dopamine release.	Haloperidol	75-86	5-hydroxytryptamine receptor 2A	Rattus norvegicus	46-52	
9181636-1	1997	In this study, both catalepsy and changes in extracellular levels of striatal dopamine (DA) and dihydroxyphenyl acetic acid (DOPAC) induced by the typical neuroleptic haloperidol (HAL) were simultaneously assessed, using intracerebral microdialysis in freely moving rats, in the presence of either the 5-HT1A agonist 8-OH-DPAT or the 5-HT2A/C antagonist ritanserin.	Haloperidol	167-178	5-hydroxytryptamine receptor 2A	Rattus norvegicus	334-340	
10646521-6	2000	Haloperidol-stimulated DA efflux (65-70%) was reduced by both SR 46349B (-32%) and the 5-HT2A/2B/2C antagonist ritanserin (-30%) but not affected by SB 206553.	Haloperidol	0-11	5-hydroxytryptamine receptor 2A	Rattus norvegicus	87-93	
8935805-10	1996	In the second study, the direct acting 5-HT2A/2C receptor agonist/hallucinogen (+)1-4-iodo-2,5-dimethoxyphenyl-2-aminopropane (DOI) consistently disrupted auditory prepulse inhibition, and this effect was blocked by MDL 100,907 but not by haloperidol.	Haloperidol	239-250	5-hydroxytryptamine receptor 2A	Rattus norvegicus	39-45	
7898773-4	1994	5-HT2A receptors: risperidone (9.07) > spiperone > chlorpromazine > clozapine > thioridazine = fluphenazine > haloperidol (6.03).	Haloperidol	125-136	5-hydroxytryptamine receptor 2A	Rattus norvegicus	0-6	
8411785-0	1993	Time course of dopamine-D2 and serotonin-5-HT2 receptor occupancy rates by haloperidol and clozapine in vivo.	Haloperidol	75-86	5-hydroxytryptamine receptor 2A	Rattus norvegicus	31-55